Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/22/2005US20050282228 Methods and compositions for activating or inhibiting vegf-d and vegf-c
12/22/2005US20050282222 Nematode PAN and ZP receptor-like sequences
12/22/2005US20050282217 Using TR10 polypeptide, which is a member of the tumor necrosis factor (TNF) receptor superfamily for inhibiting apoptosis associated with HIV infection
12/22/2005US20050282216 Purified polypeptides having IL-13 receptor activity
12/22/2005US20050282215 Isolated cytokine receptor LICR-2
12/22/2005US20050282214 Monoclonal antibodies for diagnosis, prevention and treatment of cell proliferative and immune disorders
12/22/2005US20050282165 Diagnosis of Carcinoma Using RAIG1 Polypeptides
12/22/2005US20050281895 Slimming cosmetic composition containing a substance inducing the production of IL-6
12/22/2005US20050281885 Method for treating inflammatory bowel disease by oral administration of IL-10
12/22/2005US20050281867 Nitric oxide inducing agents
12/22/2005US20050281855 Process for preparing a cross-linked carboxyl polysaccharide and the cross-linked carboxyl polysaccharide
12/22/2005US20050281846 Local administration of a botulinum toxin, especially botulinum toxin type A, to an injured muscle to facilitate healing of injured biceps, knee or shin muscles.
12/22/2005US20050281831 inhibiting vascularization or angiogenesis using chimeric proteins, immunoglobulin-like domains of tyrosine kinase receptors
12/22/2005US20050281829 Fc chimeric proteins with anti-HIV drugs
12/22/2005US20050281825 peptide transport proteins (PepTs); has antibody-dependent cell-mediated cytotoxic (ADCC) activity; cancer
12/22/2005US20050281824 Methods of using IMXP-888 and IMXP-888 antagonists
12/22/2005US20050281822 Method of administering and using VEGF inhibitors for the treatment of malignant pleural effusion
12/22/2005US20050281820 Administering to a burn an anticytokine or antiinflammatory agent and a pharmaceutically excipient; administering to a mammal having a burn injury:sodium monofluorophosphate and a dihydrofolate reductase inhibitor of aminopterin, methotrexate, pyramethamine, trimethoprim or derivatives
12/22/2005US20050281817 Method for treating multiple sclerosis
12/22/2005US20050281813 Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
12/22/2005US20050281811 Anti-lymphotoxin-beta receptor antibodies as anti-tumor agents
12/22/2005US20050281808 Peptide fragments having cell death-inhibitory activity
12/22/2005US20050281807 Use of C-reactive protein to treat immune complex-mediated renal disease
12/22/2005US20050281806 Compositions for topical enzymatic debridement
12/22/2005US20050281805 Targeted therapeutic proteins
12/22/2005US20050281804 Administering human recombinant alpha -L-iduronidase, carrier and polysorbate for therapy of mucopolysaccharidosis
12/22/2005US20050281803 Methods and compositions for using aleveolar macrophage phospholipase A2
12/22/2005US20050281802 Methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume, glue featuring an adhering moiety coupled to one or more other moieties including a cross-linkable moiety and/or one other adhering moiety; use in treating pulmonary conditions, emphysema, copd
12/22/2005US20050281801 Glue composition for lung volume reduction
12/22/2005US20050281800 Targeting sites of damaged lung tissue
12/22/2005US20050281799 Targeting damaged lung tissue using compositions
12/22/2005US20050281798 Targeting sites of damaged lung tissue using composition
12/22/2005US20050281797 Methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume, glue featuring an adhering moiety coupled to one or more other moieties including a cross-linkable moiety and/or one other adhering moiety; use in treating pulmonary conditions, emphysema, copd
12/22/2005US20050281796 Targeting damaged lung tissue
12/22/2005US20050281795 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers
12/22/2005US20050281793 T cell activation
12/22/2005US20050281792 Phytases, nucleic acids encoding them and methods of making and using them
12/22/2005US20050281787 Tumor-specific vector for gene therapy
12/22/2005US20050281780 Contacting, by ductal cannulation, the ductal epithelium of the exocrine gland with a cytolytic virus to destroy less than all of the ductal epithelium so as to inhibit formation of cancer of ductal epithelial origin
12/22/2005US20050281779 Enhancing immune responses to genetic immunization by using a chemokine
12/22/2005US20050281772 Compositions for mucosal delivery of agents
12/22/2005US20050281753 Buccal, polar and non-polar spray or capsule
12/22/2005DE19605657B4 Menschliches Proinsulinderivat, Kodierende DNA, DNA enthaltender Expressionsvektor, mit diesem transformierter Mikroorganismus und Verwendung dieses menschlichen Proinsulinderivats Human proinsulin derivative-encoding DNA, DNA-containing expression vector, transformed with this microorganism and use of this human Proinsulinderivats
12/22/2005DE10362092A1 Mit Adipositas assoziierte Proteine und deren Verwendung in Therapie und Diagnostik With obesity-associated proteins and their use in therapy and diagnosis
12/22/2005DE102004026045A1 Inhibitor für den nukleären Transkriptionsfaktor kappa B(NFxb) Inhibitor of the nuclear transcription factor kappa B (NFxb)
12/22/2005CA2573439A1 Compositions and methods for treating myocardial fibrosis comprising vasoactive intestinal peptide
12/22/2005CA2569909A1 Vaccine compositions and methods
12/22/2005CA2569788A1 Tumor specific antibody
12/22/2005CA2569662A1 Heparin binding peptide
12/22/2005CA2569137A1 Intranasal formulations of interferon beta free of stabilizers that are proteins or polypeptides
12/22/2005CA2568995E Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
12/22/2005CA2568929A1 Phosphodiesterase 10 inhibition as treatment for obesity-related and metabolic syndrome-related conditions
12/22/2005CA2568305A1 Insulin-independent, bone morphogenetic protein (bmp)-mediated uptake of blood glucose by peripheral cells and tissues
12/22/2005CA2568295A1 A method for altering the cd4/cd8 ratio and the mononuclear cellular infiltrate into a tumor
12/22/2005CA2567877A1 Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans
12/22/2005CA2567830A1 Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
12/22/2005CA2567827A1 Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons
12/22/2005CA2567205A1 Enzymatic treatment of retinitis pigmentosa and relevant pharmaceutical composition therefor in form of a kit
12/22/2005CA2567063A1 Dosage form containing the active ingredient cholylsarcosine
12/22/2005CA2566904A1 Local delivery of growth factors for stem cell transplantation
12/22/2005CA2566647A1 Inhibition of macrophage-stimulating protein receptor (ron)
12/22/2005CA2565703A1 Methods of treating disease with random copolymers
12/22/2005CA2565124A1 Peptide capable of altering tubulin polymerization and use thereof for inhibiting cell proliferation
12/22/2005CA2565101A1 Novel use of peptide compounds for treating pain in trigeminal neuralgia
12/22/2005CA2558676A1 Compositions and methods for topical diagnostic and therapeutic transport
12/21/2005EP1607744A2 Treatment of diseases involving cyst formation with combinations comprising a PTBR agonist
12/21/2005EP1607483A1 A recombinant constructed by a virus vector and a human tumor suppressor gene and its use
12/21/2005EP1607481A1 Engineered protein kinases which can utilize modified nucleotide triphosphate substrates
12/21/2005EP1607478A2 Chondroitin lyase enzymes
12/21/2005EP1607103A1 Concomitant drug as therapeutic agent for inflammatory bowel disease
12/21/2005EP1607101A1 Degradation inhibitor for hepatitis b virus x interacting protein
12/21/2005EP1607100A1 Remedy for spinal injury containing interleukin-6 antagonist
12/21/2005EP1607086A1 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
12/21/2005EP1606633A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d3 (drd3)
12/21/2005EP1606630A2 Diagnostics and therapeutics for diseases associated with dopamine receptor d4 (drd4)
12/21/2005EP1606625A1 Use of substances inhibiting the association of smad protein with ubiquitin c-terminal hydrolase for altering cellular responses to tgf-beta or bmp
12/21/2005EP1606621A2 Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar)
12/21/2005EP1606411A1 Mutant vesicular stomatitis viruses and use thereof
12/21/2005EP1606409A2 Nogo receptor binding protein
12/21/2005EP1606407A2 Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
12/21/2005EP1606406A2 SHORT INTERFERING RNA (siRNA) ANALOGUES
12/21/2005EP1606405A2 Compounds and their use for specific and simultaneous inhibition of genes involved in diseases and related drugs
12/21/2005EP1606403A2 Hemipteran glutamate decarboxylase
12/21/2005EP1606401A1 Treatment of infection due to clostridium difficile
12/21/2005EP1606396A2 Methods of promoting the differentiation of stem cells
12/21/2005EP1606313A2 Specific inhibition of allograft rejection
12/21/2005EP1606312A2 Baff mutants with at least one amino acid substitution and methods of their production
12/21/2005EP1606310A2 Secreted protein family
12/21/2005EP1606309A2 Antimicrobial agents from streptococcus mitis and streptococcus oralis
12/21/2005EP1606308A2 Tumour-associated peptides binding to mhc molecules
12/21/2005EP1606305A2 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
12/21/2005EP1606018A2 Use of thyroid-stimulating hormone to induce lipolysis
12/21/2005EP1605969A1 Angiotensin-converting enzyme inhibitory peptides
12/21/2005EP1605968A2 Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
12/21/2005EP1605967A1 Novel nph insulin preparations
12/21/2005EP1605966A1 Use of chemokine receptor agonists for stem cell transplantation
12/21/2005EP1605965A1 Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
12/21/2005EP1605964A1 TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE
12/21/2005EP1605963A2 Inhibitors of antigen presentation by mhc class ii molecules and methods of use thereof
12/21/2005EP1605962A1 Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy
1 ... 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 ... 3163